ABBOTT LABORATORIES Q2 FY26 Results

Summary

Abbott announced strong second-quarter results, with reported sales up 13.0% and comparable sales up 4.8%. The company reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. Abbott raised its full-year 2026 adjusted diluted EPS guidance to $5.45-$5.60 and reaffirmed its comparable sales growth guidance of 6.5%-7.5%. Management expressed confidence in continued momentum driving accelerating sales and earnings growth in the second half of the year.

Key Highlights

1. 1

   Abbott reported second-quarter sales growth of 13.0 percent on a reported basis and 4.8 percent on a comparable basis.

2. 2

   Second-quarter GAAP diluted EPS was $0.53, while adjusted diluted EPS was $1.31.

3. 3

   The company reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%.

4. 4

   Abbott raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, up from the previous range of $5.38 to $5.58.

5. 5

   Abbott returned $2.1 billion to shareholders in the second quarter through dividends and share repurchases.

6. 6

   Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.

7. 7

   Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.